The study focuses on adults who have overweight or obesity together with type 2 diabetes. These conditions mean that a person carries excess body weight and has difficulty controlling blood sugar levels. The investigational medicine is called olatorepatide, which is described as a GLP-1/GIP receptor agonist. This type of medicine works by helping the body use insulin better and can also reduce appetite, which may lead to weight loss. The drug is given as a small injection under the skin.
The purpose of the trial is to determine whether olatorepatide leads to greater weight loss than placebo. Participants will be randomly assigned to receive either the study medicine or a placebo injection and will be followed for several months. During the study they will have regular check‑ups to measure their body weight, blood sugar control using HbA1c (a lab test that shows average blood sugar over the past few months) and fasting plasma glucose (blood sugar after an overnight fast), and other health markers such as homeostatic model assessment for insulin resistance, systolic blood pressure, diastolic blood pressure, cholesterol numbers including LDL‑C, HDL‑C and VLDL‑C, inflammation measured by hs‑CRP, and kidney function using uACR. Safety will be monitored by checking for any anti‑drug antibody or neutralizing antibody responses and for any treatment‑emergent adverse events that may occur.
Germany 
